



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 66478

**Title:** New drugs for the treatment of metastatic colorectal cancer

**Reviewer's code:** 04123904

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Chief Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-04-02

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-28 06:55

**Reviewer performed review:** 2021-04-28 08:46

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors reviewed the current status and future perspective of the treatment for the metastatic colorectal cancer. This is a well written article but some concerns should be addressed. Minor comments 1) As described in the guidelines for authors, abbreviations should be defined in the abstract and in the main body of the manuscript upon first mention in the text, except for certain commonly used abbreviations such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, and mAb. In addition, the authors don't need to define the same abbreviation (e.g. OS) multiple times in the text. Some abbreviations such as VEGF, EGFR, PFS, and OS should be defined in the text according to the guidelines. 2) What is the difference between mCRC and CRCm? To avoid confusion for the readers, the abbreviation for metastatic colorectal cancer should be unified to mCRC or CRCm. 3) This manuscript has no Figures and Tables. The authors should include some Figures or Tables in the text for a better understanding of the readers.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 66478

**Title:** New drugs for the treatment of metastatic colorectal cancer

**Reviewer's code:** 05400628

**Position:** Peer Reviewer

**Academic degree:** BSc, MD

**Professional title:** Occupational Physician

**Reviewer's Country/Territory:** Spain

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-04-02

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-28 23:08

**Reviewer performed review:** 2021-05-06 18:59

**Review time:** 7 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

I think the authors gave a great view of the current and future treatments for CCR. Great review article. However, there are some English corrections to be made. Please find my comments attached